Skip to main content
    C

    Chemomab Therapeutics Ltd DRC (CMMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.29
    +0.00 (+0.00%)

    Market Cap: $9.09M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(21/29)
    Avg Surprise
    -82.13%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26
    Reported Oct 15
    		$-1.40$0.00N/ABeat-34900.0%
    Jun 26
    Reported Aug 19
    		$-1.40$0.00N/AMiss-6900.0%
    Mar 26
    Reported May 14
    		$-0.00$0.00N/AMiss+97.9%
    Dec 25
    Reported Mar 19
    		$-0.00N/A+70.00%Beat+62.5%
    Sep 25
    Reported Nov 13
    		$-0.00N/A+90.00%Beat+90.0%
    Jun 25
    Reported Aug 14
    		$-0.02$-0.04+50.00%Beat-140.0%
    Mar 25
    Reported May 15
    		$-0.14$-0.20+30.00%Beat-133.3%
    Dec 24
    Reported Mar 3
    		$-0.01$-0.01+20.00%Beat+97.0%
    Sep 24
    Reported Nov 14
    		$-0.04$-0.04+0.00%Beat+42.9%
    Jun 24
    Reported Aug 21
    		$0.05$-0.04+225.00%Beat+135.7%
    Mar 24
    Reported May 9
    		$-0.06$-0.06+0.00%Beat+62.5%
    Dec 23
    Reported Mar 7
    		$-0.27$-0.02-1227.00%Miss-89.6%
    Sep 23
    Reported Nov 9
    		$-0.07$-0.08+12.50%Beat+50.0%
    Jun 23
    Reported Aug 14
    		$-0.14$-0.16+12.50%Beat-27.3%
    Mar 23
    Reported May 11
    		$-0.16$-0.14-14.29%Miss-77.8%
    Dec 22
    Reported Mar 20
    		$-0.14$-0.12-16.67%Miss+68.2%
    Sep 22
    Reported Nov 11
    		$-0.14N/A+84.78%Beat-180.0%
    Jun 22
    Reported Aug 12
    		$-0.11N/A+84.72%Beat-120.0%
    Mar 22
    Reported May 12
    		$-0.09N/A+86.76%Beat-125.0%
    Dec 21
    Reported Mar 9
    		$-0.44$-0.10-340.00%Miss-633.3%
    Sep 21
    Reported Nov 12
    		$-0.05$-0.06+16.67%Beat+44.4%
    Jun 21
    Reported Aug 13
    		$-0.05N/A+89.13%Beat+44.4%
    Mar 21
    Reported May 13
    		$-0.04N/A+97.67%Beat+99.5%
    Dec 20
    Reported Mar 9
    		$-0.06N/A+96.25%Beat-100.2%
    Sep 20
    Reported Nov 16
    		$-0.09$-0.09+0.00%Beat+99.7%
    Jun 20
    Reported Aug 14
    		$-0.09$-0.11+18.18%Beat+97.8%
    Mar 20
    Reported May 7
    		$-8.00$-1.84-334.78%Miss+85.7%
    Dec 19
    Reported Mar 17
    		$31.20$-2.00+1660.00%Beat+26100.0%
    Sep 19
    Reported Nov 15
    		$-34.40$-2.93-1074.06%Miss-
    Jun 19
    Reported Aug 5
    		$-4.00$-2.64-51.52%Miss-
    Mar 19
    Reported May 22
    		$-56.00$-2.56-2087.50%Miss-
    Dec 18
    Reported Mar 12
    		$-0.12$-0.15+20.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.46EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-82.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.41xQuick Ratio6.41x
    Trading Statistics
    Beta0.74Avg Volume130.76K
    52-Week High$3.4552-Week Low$1.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.36
    SMA 20$1.67
    SMA 50$2.08
    SMA 200$1.79
    EMA 10$1.40
    EMA 20$1.62
    EMA 50$1.87
    EMA 200$2.07

    MACD

    Line: -0.27Signal: -0.25Hist: -0.02

    ADX

    ADX: 39.1+DI: 14.4-DI: 30.4

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down56.0
    PSAR$1.42

    Bollinger Bands

    Upper Band$2.62
    Lower Band$0.72
    %B Position11396%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    30.3

    Momentum Oscillators

    Stoch %K18.5
    Stoch %D19.7
    Williams %R-79.6
    ROC (10d)-0.8%
    Momentum-0.01
    CCI (20d)-64.4
    MFI (14d)19.7

    Volatility Measures

    ATR (14d)$0.18(14.0%)
    StdDev (20d)0.48
    Hist Vol140.3%(High)

    Volume Flow

    VWAP$1.30
    OBV-3.3M
    AD Line1.3B
    CMF (20d)-0.499

    Volume Metrics

    Avg Vol (20d)131.6K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.66

    Pivot Points

    R3$1.42
    R2$1.38
    R1$1.34
    Pivot Point$1.30
    S1$1.25
    S2$1.21
    S3$1.17

    Advanced Oscillators

    TSI-38.49
    Ultimate Osc23.5
    KST-407.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/A$33,687N/AN/AN/A$26,901N/A$16,173$18,932
    Gross ProfitN/AN/AN/AN/A$-33,687N/AN/AN/A$-26,901N/A$-16,173$-18,932
    Operating Expenses$2.28M$1.85M$1.99M$1.84M$2.26M$3.49M$3.21M$3.71M$3.73M$4.09M$3.87M$4.33M
    R&D$1.16M$925,000$1.10M$960,000$1.29M$2.49M$2.41M$2.84M$2.89M$3.15M$3.11M$3.35M
    SG&A$1.10M$925,000$881,000$884,000$975,000$994,000$802,000$874,000$840,000$896,000$751,000$990,000
    Operating Income$-2,279,481$-1,850,000$-1,986,330$-1,844,000$-2,262,000$-3,487,000$-3,213,000$-3,710,000$-3,754,264$-4,092,907$-3,889,707$-4,351,465
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$500$1,996$0$0
    Income Before Tax$-2,202,176$-1,773,000$-1,884,699$-1,742,000$-2,057,000$-3,323,000$-2,963,000$-3,483,000$-3,617,763$-3,910,910$-3,454,035$-4,121,287
    Income Tax Expense$0$0$0$0$0$0$0$0$-2$-16,751$-1$-54,804
    Net Income$-2,202,176$-1,773,000$-1,884,699$-1,742,000$-2,057,000$-3,323,000$-2,963,000$-3,483,000$-3,617,763$-3,910,910$-3,454,035$-4,066,482
    EBITDA$-2,279,481$-1,832,500$-1,968,830$-1,830,750$-2,245,500$-3,473,750$-3,196,250$-3,693,250$-3,727,363$-4,092,907$-3,873,534$-4,332,533
    EBIT$-2,241,000$-1,850,000$-1,986,330$-1,844,000$-2,262,000$-3,487,000$-3,213,000$-3,710,000$-3,754,264$-4,048,000$-3,889,707$-4,351,465
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CMMB

    News

    Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

    Chemomab Therapeutics, a clinical-stage biotechnology company, announced its participation in the 2023 Aegis Virtual Conference, where its management will present a corporate overview on May 3...

    Lelezard•10/7/26•Somewhat-Bullish

    Price to book forward of Chemomab Therapeutics Ltd. – NASDAQ:CMMB

    The article provides financial data for Chemomab Therapeutics Ltd. (NASDAQ: CMMB), specifically focusing on its price to book forward ratio. It highlights that the market was closed at the time of publication and offers...

    TradingView•10/4/26•Neutral

    Ownership split stays unchanged as Chemomab (CMMB) amends its Scipher merger terms.

    Chemomab Therapeutics Ltd. has amended its domestication merger agreement with Snowdrift Parent Corporation and Elderwood Ltd....

    Stock Titan•10/1/26•Neutral

    Chemomab Therapeutics Updates Merger Agreement with Scipher Medicine Corporation

    Chemomab Therapeutics Ltd. has announced a technical amendment to its merger agreement with Scipher Medicine Corporation. This amendment establishes a formula-based exchange ratio for shares...

    Kalkine Media•9/30/26•Neutral

    Chemomab at H.C. Wainwright conference: merger sets ra push

    Chemomab Therapeutics (CMMB) announced a strategic merger with Scipher Medicine and a shift in focus to developing nebokitug for rheumatoid arthritis at the H.C. Wainwright conference. The combined entity...

    Investing.com India•9/11/26•Bullish

    CMMB Valuation and Fair Value

    P/E
    -0.5x
    Forward P/E
    12.9x
    P/B
    1.2x
    See GNG's fair value

    CMMB Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -82.2%

    CMMB Competitors

    CompanyTicker
    Check Cap LtdCHEK
    MetaVia Inc.MTVA
    VistaGen Therapeutics IncVTGN
    Moleculin Biotech IncMBRX
    Theriva Biologics Inc.TOVX
    Immuron Ltd ADRIMRN
    Neuroone Medical Technologies CorpNMTC
    American Shared Hospital ServiceAMS

    Sector: Healthcare

    CMMB Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    52.0%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.02

    Frequently Asked Questions About CMMB

    Does CMMB pay dividends?

    Chemomab Therapeutics Ltd DRC (CMMB) does not currently pay a regular dividend.

    What is CMMB's market cap?

    Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalization of $9.09M with a current stock price of $1.29.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In